Disease | thrombocytopenia |
Comorbidity | C0027947|neutropenia |
Sentences | 25 |
PubMedID- 19652971 | Grade 3/4 toxicities included neutropenia (33.9% of patients) and thrombocytopenia (7.6%). |
PubMedID- 20556612 | In the present study, grade 3–4 hematologic toxicities, including neutropenia, developed in 51.0% of patients, thrombocytopenia developed in 2.0%, and anemia developed in 20.4%. |
PubMedID- 21116412 | Dose limiting toxicities according to the manufacturer’s spc: anc < 500/μl for more than five days or neutropenia associated with fever/infection; thrombocytopenia < 25.000/μl; bilirubin > uln; ap > 2.5× uln; ast/alt > 2.5× uln. |
PubMedID- 23782157 | Grade 3 or higher hematologic events were infrequent and included neutropenia (in 16% of patients), thrombocytopenia (in 11%), and anemia (in 10%). |
PubMedID- 20178634 | Wiskott-aldrich syndrome is an x-linked disorder characterized by current infection, thrombocytopenia (with small platelets), neutropenia, eczema, high ige levels, a very high prevalence of autoimmunity (including arthropathy, vasculitis, and inflammatory bowel disease) and malignancy. |
PubMedID- 25042202 | The most common grade 3 or greater adverse events included neutropenia (73% [24 of 33 patients]), thrombocytopenia (21% [seven patients]), and febrile neutropenia and anaemia (18% each [six patients]). |
PubMedID- 24155675 | Overall adverse events according to ctcae v.3.0 during chemotherapy are shown in table 4. the most common grade 3/4 hematologic toxicity was neutropenia, with an incidence of 12%, followed by thrombocytopenia (10%). |
PubMedID- 26090398 | The most common grade ≥3 toxicities observed were neutropenia in 85.2% of the cycles, thrombocytopenia in 25.2%, febrile neutropenia in 25.2%, neutropenic enterocolitis in 6%, and mucositis in 5.2%. |
PubMedID- 24535315 | Transient neutropenia (50 % of patients) and thrombocytopenia (33-38 %) were the most common severe hematological abnormalities; their incidence was higher than with single-agent pm00104. |
PubMedID- 21783417 | Chemotherapy was associated with more grade 3 or 4 toxic effects than was erlotinib (including neutropenia in 30 [42%] of 72 patients and thrombocytopenia in 29 [40%] patients on chemotherapy vs no patients with either event on erlotinib); the most common grade 3 or 4 toxic effects with erlotinib were increased alanine aminotransferase concentrations (three [4%] of 83 patients) and skin rash (two [2%] patients). |
PubMedID- 24611018 | Erlotinib was associated with less grade 3 or 4 toxic effects than chemotherapy (including neutropenia in 30 of 72 patients and thrombocytopenia in 29 patients on chemotherapy versus no patients with either event on erlotinib); the most common grade 3 or 4 toxic effects with erlotinib were increased alanine aminotransferase concentrations (4%, three of 83) and skin rash (2%, two of 83). |
PubMedID- 25031949 | Familiarity with factors predictive of high-risk febrile neutropenia, bleeding due to thrombocytopenia, and cardiopulmonary compromise due to anemia will provide the advanced practitioner (ap) in oncology with critical tools for rapid identification of patients at risk, prompt implementation of established guidelines for management, and avoidance of clinical deterioration. |
PubMedID- 21949519 | Thus, vsga or sga infants are particularly vulnerable to bleeding with thrombocytopenia or infection associated with neutropenia especially early after birth. |
PubMedID- 23482784 | Grade 3/4 toxicity encountered during the first cycle included g3/g4 neutropenia in 65% of patients (12/14), g3/g4 thrombocytopenia in 48% (18/1), g3 febrile neutropenia in 5% (2), g3 nausea in 5% (2), g3 diarrhea in 5% (2), and g3 fatigue in 5% of patients (2). |
PubMedID- 21458256 | Grade 3-4 toxicities included neutropenia in 83% of patients, thrombocytopenia in 47%, anaemia in 60%, infection in 23%, and diarrhoea in 20%. |
PubMedID- 23788967 | The most common hematologic adverse events were neutropenia (20% of cycles) and thrombocytopenia (4%), with grade 3/4 incidence of 8% and 1.5% [according to national cancer institute common toxicity criteria (nci ctc)]. |
PubMedID- 20187098 | The main grade 3/4 toxicity was neutropenia in 18% of cycles followed by thrombocytopenia in 9% of cycles, nausea/vomiting in 5% of cycles, and febrile neutropenia, fatigue, anemia, and stomatitis in 2% of cycles. |
PubMedID- 24299473 | Evans syndrome (es) is a rare hematological disease commonly defined by the combination of simultaneous or sequential autoimmune hemolytic anemia (aiha) and immune thrombocytopenia (itp) sometimes associated with neutropenia in the absence of known underlying etiology. |
PubMedID- 23812930 | Grade 3-4 hematologic adverse events were: neutropenia in 28% of the courses, thrombocytopenia in 9%, and anemia in 3%. |
PubMedID- 21278245 | The most common grade 3 or higher adverse events were neutropenia (49% of patients), thrombocytopenia (16%), fatigue (16%), lymphopenia (14%), and febrile neutropenia (7%). |
PubMedID- 21610706 | Dose-limiting toxicities consisted exclusively of myelosuppression (neutropenia with or without thrombocytopenia), leading to a delay in initiation of cycle 2 dosing. |
PubMedID- 26413372 | If patients experience grade 4 febrile neutropenia (fever of 38.5°c) or thrombocytopenia that requires platelet transfusion, treatment with romidepsin should be delayed. |
PubMedID- 22941346 | Grade 3 or higher toxicity included neutropenia in 17.9 % of the patients, thrombocytopenia in 5.1 % and nausea in 7.7 %. |
PubMedID- 22993584 | Grade 3-4 neutropenia occurred in 57% of patients, thrombocytopenia and anemia in 2% of cases. |
PubMedID- 21455428 | [9–11] typically, the platelet count falls to 80% of the normal and thrombocytopenia may be associated with neutropenia and anemia. |
Page: 1